-
Company Insights
Innovation and Patenting activity of Xiamen C&D Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Xiamen C&D Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Xiamen Faratronic Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Xiamen Faratronic Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
Innovation and Patenting activity of Xiamen Tungsten Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Xiamen Tungsten Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zurletrectinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zurletrectinib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zurletrectinib in Solid Tumor Drug Details: Zurletrectinib (ICP-723) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Idiopathic Short Stature
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPEG-Somatropin in Idiopathic Short Stature report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPEG-Somatropin in Idiopathic Short Stature Drug Details: YPEG-somatropin is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Turner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPEG-Somatropin in Turner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPEG-Somatropin in Turner Syndrome Drug Details: YPEG-somatropin is under development for the...
-
Product Insights
Growth Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Growth Disorders - Drugs In Development, 2023’, provides an overview of the Growth Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Growth Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Idiopathic Short Stature – Drugs In Development, 2023
Global Markets Direct’s, ‘Idiopathic Short Stature - Drugs In Development, 2023’, provides an overview of the Idiopathic Short Stature pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic Short Stature, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Turner Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Turner Syndrome - Drugs In Development, 2023’, provides an overview of the Turner Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Turner Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...